Since 1988, more than 700 000 renal, hepatic, and cardiothoracic transplants have been performed in the United States. Transplant immunosuppression increases the risk of cutaneous squamous cell carcinoma (cSCC) by 65 to 200 times compared with the nontransplant population.
1
Patients who have received transplants have a local recurrence risk ranging from 10% to 40%, with up to 8% of lesions ultimately metastasizing to other sites. 5 That we know of, there are currently no published reports regarding the mean number of cSCC experienced in the 3 largest organ transplant groups or the timing of second primary cSCC.
Methods | Approval from the Duke University institutional review board was obtained, as were waivers of patient consent. A retrospective study spanning from January 1996 to December 2016 was conducted of renal, hepatic, and cardiothoracic adult (age >18 years) transplant patients at Duke Medical Center. Pretransplant cSCC was the only exclusion criterion. Results | Overall, 3652 SOTRs were identified; cSCCs developed in 143 patients (3.9%) at a mean (SD) follow-up time of 7.2 (4.0) years after transplantation ( Table 1 ). The mean (SD) age at transplantation was 59.3 (9.2) years. Of the 143 patients, the mean (SD) number of cSCCs experienced was 2.6 (4.2) over the mean follow-up time, with an interquartile range of 2 cSCCs. Twenty patients (14.0%) experienced their second cSCC within 6 months of their initial posttransplant cSCC.
The renal group experienced a mean (SD) of 3.0 (4.1) cSCCs compared with 2.4 (2.0) cSCCs in the hepatic group and 2.6 (3.0) cSCCs in the cardiothoracic group (P = .60). Seventy-six patients (52.8%) experienced 2 or more cSCCs, with the mean (SD) latency time between first cSCC and second cSCC of 1.9 (2.0) years. Group 1 was defined as those patients who experienced only 1 cSCC after transplant and comprised 67 patients (46.9%), whereas group 2 was defined as those patients who developed at least 2 cSCCs following transplantation and comprised 76 patients (53.1%). Immunosuppressive regimen use is compared between groups in Table 2 .
Discussion | More than half of SOTRs who develop cSCCs will experience a new primary lesion, but the latency period between the first and second posttransplant cSCC varied widely in our study. While group 1 had a higher exposure to voriconazole and mycophenolate, the SOTRs in group 2 had a greater exposure to azathioprine. The confounding factors, such as use of immunosuppression medications and similar baseline personal risk factors (eg, male sex, age, and prior history of actinic keratosis), underscore the difficulty in predicting which SOTRs will develop a new primary cSCC and which will not. This study's major limitation is its retrospective, singlecenter nature. Fitzpatrick skin phototype information was also not available in our cohort.
Conclusions | In this study, SOTRs experienced an average of 2.6 cSCCs over a mean follow-up of 7.2 years with an average of 1.9 years elapsing between diagnosis of the first and second cSCC. It is difficult to predict which SOTRs will experience a second primary cSCC following transplant. Therefore, ongoing vigilance with frequent dermatologic surveillance beyond the first 2 to 3 years after the initial posttransplant cSSC diagnosis should be considered owing to the increased risk in this population.
